| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b04f067358421e8f3cf5f6d8e5313e07 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-95
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D211-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D459-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-475
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C381-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-95
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-475
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D459-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C381-00 |
| filingDate |
2000-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4a40479ab49fe0df9fcf9d3ef76828da
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df76163b41295b8a15c0e5da0b4de19a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_42392e37dd499e8af5c20f9ecdb20141 |
| publicationDate |
2002-01-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1164848-A1 |
| titleOfInvention |
Compositions and methods for preventing and treating sexual dysfunctions |
| abstract |
The present invention describes methods for preventing and treating sexual dysfunctions in male and female patients by orally administering at least one α-adrenergic receptor antagonist and at least one compound that elevates endogenous nitric oxide or endothelium-derived relaxing factor in vivo or is a substrate for nitric oxide synthase. The present invention also describes orally administrable compositions comprising at least one α-adrenergic receptor antagonist and at least one compound that elevates endogenous nitric oxide or endothelium-derived relaxing factor in vivo or is a substrate for nitric oxide synthase. In the present invention, the α-adrenergic receptor antagonist is preferably yohimbine or phentolamine, and the compound that elevates endogenous nitric oxide or endothelium-derived relaxing factor in vivo or is a substrate for nitric oxide synthase is preferably L-arginine. In preferred embodiments, the present invention provides a sachet comprising an orally administrable single dose composition of L-arginine and/or a pharmaceutically acceptable salt thereof and yohimbine and/or a pharmaceutically acceptable salt thereof. |
| priorityDate |
1999-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |